SLVM

Sylvamo is a low-cost uncoated-freesheet producer trading at a genuinely undemanding 11.6x trailing EPS and 0.4x sales, with a market cap of $1.48B against $966M of equity, $2.51B of retained earnings and a 1.5x current ratio ($1.08B current assets vs $716M current liabilities). On the surface that screams value. But the 2025 numbers show a sharp cyclical and structural deterioration, not a one-quarter wobble: revenue fell 11.2% to $3.35B, operating income dropped 44.6% to $251M, net income fell 56.3% to $132M, and diluted EPS more than halved to $3.24. Management's own MD&A frames the decline as broad — lower uncoated-freesheet volumes across all three regions, unfavorable price/mix in Europe and Latin America, higher input costs everywhere, two European maintenance outages, and FX translation headwinds. Adjusted EBITDA fell from $632M (17% margin) to $448M (13%), confirming the squeeze is operational, not optical.

The bigger problem for a 'buy' is the forward picture management itself paints. The 10-K calls 2026 'a transition year for North America' as it absorbs the Riverdale supply-agreement exit and executes Eastover mill investments amid 'short-term capacity constraints' — i.e., don't expect 2026 to bail out the multiple. The cash story underlines the caution: operating cash flow fell 42.9% to $268M while capex held at $224M, leaving only $44M of free cash flow (down from $248M). Yet the company returned $155M to shareowners ($82M buybacks + $73M dividends) — well above FCF — and cash fell 34.1% to $135M. The dividend is covered by FCF only on its own; total shareholder returns are currently being part-funded from the balance sheet, which is sustainable for a year or two but not indefinitely if the downcycle persists.